ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.07
0.46%
US Tech 100
17,244.80
1.57%
S&P 500
5,099.96
1.02%
US Dollar vs CAD
1.36805
0.00%
Bitcoin
63,746.38
0.53%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. UK
  5. LSE
  6. Nicox Sa (0RCQ)

  7. Nicox Sa (0RCQ) News

0RCQ

Nicox (0RCQ)

Nicox Sa
Date:
Sort by:
 Showing the most relevant articles for your search:LSE:0RCQ
DateTimeSourceHeadlineSymbolCompany
03/20/20241:30AMUK RegulatoryNicox : Publication de résultats de l’étude de phase 3 Mont Blanc sur le NCX 470 dans le glaucome dans la revue American Journal of OphthalmologyLSE:0RCQNicox Sa
03/20/20241:30AMUK RegulatoryResults from Mont Blanc Phase 3 Trial of Nicox’s NCX 470 in Glaucoma Published in the American Journal of OphthalmologyLSE:0RCQNicox Sa
03/13/20241:30AMUK RegulatoryNicox fait le point sur les perspectives de son développement, de son portefeuille de produits et de son financement et tiendra une réunion par webcast le 18 mars 2024LSE:0RCQNicox Sa
03/13/20241:30AMUK RegulatoryNicox Updates on Corporate, Pipeline and Financing Perspectives and Will Hold a Webcast on March 18, 2024LSE:0RCQNicox Sa
03/05/202412:30AMUK RegulatoryNicox Announces Presentation of Data on NCX 470 at the 2024 American Glaucoma Society Annual MeetingLSE:0RCQNicox Sa
03/05/202412:30AMUK RegulatoryNicox : Présentation de données sur le NCX 470 au Congrès Annuel 2024 de l’American Glaucoma SocietyLSE:0RCQNicox Sa
03/01/202410:45AMUK RegulatoryNumber of voting rights as of February 29, 2024LSE:0RCQNicox Sa
03/01/202410:45AMUK RegulatoryNombre de droits de vote au 29 février 2024LSE:0RCQNicox Sa
02/28/202412:30AMUK RegulatoryNicox Appoints Experienced Biotech Executive Gavin Spencer as CEOLSE:0RCQNicox Sa
02/28/202412:30AMUK RegulatoryNicox restructure sa dette et réduit sa structure pour étendre son horizon de trésorerie et prioriser les ressources sur l’étude pivotale sur le NCX 470LSE:0RCQNicox Sa
02/28/202412:30AMUK RegulatoryGavin Spencer, dirigeant expérimenté du secteur de la biotechnologie, nommé Directeur Général de NicoxLSE:0RCQNicox Sa
02/28/202412:30AMUK RegulatoryNicox Restructures Debt, Streamlines Operations to Extend Cash Runway and Focus Resources on NCX 470 Pivotal TrialLSE:0RCQNicox Sa
02/08/202412:30AMUK RegulatoryNicox : Contrat de licence avec la société Kowa pour le développement et la commercialisation du NCX 470 au JaponLSE:0RCQNicox Sa
02/08/202412:30AMUK RegulatoryNicox and Kowa Enter into Agreement for NCX 470 Development and Commercialization in JapanLSE:0RCQNicox Sa
02/06/202412:30AMUK RegulatoryNicox announces presentations at the upcoming Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting 2024LSE:0RCQNicox Sa
02/06/202412:30AMUK RegulatoryNicox : Présentations au prochain Congrès Annuel 2024 de l’Association for Research in Vision and Ophthalmology (ARVO)LSE:0RCQNicox Sa
02/01/202410:45AMUK RegulatoryNombre de droits de vote au 31 janvier 2024LSE:0RCQNicox Sa
02/01/202410:45AMUK RegulatoryNumber of votings rights as of January 31 2024LSE:0RCQNicox Sa
01/31/202412:30AMUK RegulatoryNicox Receives Confirmation of 5-year Patent Term Extension of U.S. Patent for Latanoprostene Bunod, Commercialized as VYZULTA®LSE:0RCQNicox Sa
01/31/202412:30AMUK RegulatoryNicox : Prolongation de 5 ans de la durée d’un brevet américain couvrant le latanoprostene bunod commercialisé sous le nom de VYZULTA®LSE:0RCQNicox Sa
01/25/202412:30AMUK RegulatoryNicox : Résumé financier et point d’activité du quatrième trimestre 2023LSE:0RCQNicox Sa
01/25/202412:30AMUK RegulatoryNicox Provides Fourth Quarter 2023 Financial and Business HighlightsLSE:0RCQNicox Sa
 Showing the most relevant articles for your search:LSE:0RCQ

Your Recent History

USOTC
VXIT
Virexit Technologies (PK)
NYSE
AMC
AMC Entertainment
USOTC
KEGS
1812 Brewing (PK)
USOTC
IPIX
Innovation Pharmaceuticals (CE)
NASDAQ
AMRN
Amarin
USOTC
AABB
Asia Broadband (PK)
USOTC
INND
Innerscope Hearing Techn... (PK)
USOTC
CBIA
Canopus Biopharma (PK)
USOTC
TPTW
TPT Global Tech (CE)
USOTC
GVSI
Good Vibrations Shoes (PK)
USOTC
BEGI
BlackStar Enterprise (PK)
USOTC
SPZI
Spooz (PK)
COIN
SHIBUSD
SHIBA INU
USOTC
NWBO
Northwest Biotherapeutics (QB)
NASDAQ
NB
NioCorp Developments
USOTC
FNMA
Fannie Mae (QB)
Delayed Upgrade Clock
ADVFN Logo

Canada
Company
Business
Popular
Get The App

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved